MYC, MYCL, and MYCN as therapeutic targets in lung cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2019. [cited 2019 Sep 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
   Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
   PubMed Web of Science ®Google Scholar
• Warren GW, Cummings KM. Tobacco and lung cancer: risks, trends, and outcomes in patients with cancer. Am Soc Clin Oncol Educ book Am Soc Clin Oncol Annu Meeting. 2013;359–364.
   PubMedGoogle Scholar
• Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO classification. Front Oncol. 2017;7:193.
   PubMed Web of Science ®Google Scholar
• Sutherland KD, Berns A. Cell of origin of lung cancer. Mol Oncol. 2010;4(5):397–403.
   PubMed Web of Science ®Google Scholar
• Rajdev K, Siddiqui AH, Ibrahim U, et al. An unusually aggressive large cell carcinoma of the lung: undiagnosed until autopsy. Cureus. 2018;10(2):e2202.
   PubMed Web of Science ®Google Scholar
• Corrales L, Nogueira A, Passiglia F, et al. Second-line treatment of non-small cell lung cancer: clinical, pathological, and molecular aspects of nintedanib. Front Med (Lausanne). 2017;4:13.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
   PubMed Web of Science ®Google Scholar
• Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5(9):2892–2911.
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Leonardi GC, Metro G, et al. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Rev Respir Med. 2016;10(1):53–68.
   PubMed Web of Science ®Google Scholar
• Iwakawa R, Kohno T, Kato M, et al. MYC amplification as a prognostic marker of early-stage lung adenocarcinoma identified by whole genome copy number analysis. Clin Cancer Res. 2011;17(6):1481–1489.
   PubMed Web of Science ®Google Scholar
• Schaub FX, Dhankani V, Berger AC, et al. Pan-cancer alterations of the myc oncogene and its proximal network across the cancer genome atlas. Cell Systems. 2018;6(3):282–300.e2.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25(15):4592–4602.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9):1240–1242.
   PubMed Web of Science ®Google Scholar
• Nicholson AG, Chansky K, Crowley J, et al. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(3):300–311.
   PubMed Web of Science ®Google Scholar
• Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. YSONC. 2001;28(2 Suppl 4):3–13.
   Google Scholar
• George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53.
   PubMed Web of Science ®Google Scholar
• Mollaoglu G, Guthrie MR, Böhm S, et al. MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Cancer Cell. 2017;31(2):270–285.
   PubMed Web of Science ®Google Scholar
• Semenova EA, Nagel R, Berns A. Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev. 2015;29(14):1447–1462.
   PubMed Web of Science ®Google Scholar
• Jiang SX, Sato Y, Kuwao S, et al. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol. 1995;177(2):135–138.
   PubMed Web of Science ®Google Scholar
• Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res. 2016;5(1):26–38.
   PubMed Web of Science ®Google Scholar
• Wagner AH, Devarakonda S, Skidmore ZL, et al. Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nat Comms. 2018;9(1):3787.
   PubMedGoogle Scholar
• Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12(1):47.
   PubMedGoogle Scholar
• Calles A, Aguado G, Sandoval C, et al. The role of immunotherapy in small cell lung cancer. Clin Transl Oncol. 2019;21(8):961–976.
   PubMed Web of Science ®Google Scholar
• Lavigne P, Crump MP, Gagné SM, et al. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper. J Mol Biol. 1998;281(1):165–181.
   PubMed Web of Science ®Google Scholar
• Mcduff F-O, Naud J-F, Montagne M, et al. The Max homodimeric b-HLH-LZ significantly interferes with the specific heterodimerization between the c-Myc and Max b-HLH-LZ in absence of DNA: a quantitative analysis. J Mol Recognit. 2009;22(4):261–269.
   PubMed Web of Science ®Google Scholar
• Panova S, Cliff MJ, Macek P, et al. Mapping hidden residual structure within the Myc bHLH-LZ domain using chemical denaturant titration. Structure. 2019 Oct 1;27(10):1537–1546.
   PubMed Web of Science ®Google Scholar
• Amati B, Dalton S, Brooks MW, et al. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature. 1992;359(6394):423–426.
   PubMed Web of Science ®Google Scholar
• Mao DYL, Watson JD, Yan PS, et al. Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol. 2003;13(10):882–886.
   PubMed Web of Science ®Google Scholar
• Blackwood EM, Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991;251(4998):1211–1217.
   PubMed Web of Science ®Google Scholar
• Cole MD. MYC association with cancer risk and a new model of MYC-mediated repression. Cold Spring Harb Perspect Med. 2014;4(7):a014316.
   PubMed Web of Science ®Google Scholar
• Duesberg PH, Bister K, Vogt PK. The RNA of avian acute leukemia virus MC29. Proc Natl Acad Sci USA. 1977;74(10):4320–4324.
   PubMed Web of Science ®Google Scholar
• Sheiness D, Fanshier L, Bishop JM. Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29. J Virol. 1978;28(2):600–610.
   PubMed Web of Science ®Google Scholar
• Vennstrom B, Sheiness D, Zabielski J, et al. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol. 1982;42(3):773–779.
   PubMed Web of Science ®Google Scholar
• Roussel M, Saule S, Lagrou C, et al. Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation. Nature. 1979;281(5731):452–455.
   PubMed Web of Science ®Google Scholar
• Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–990.
   PubMed Web of Science ®Google Scholar
• Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 1982;79(24):7824–7827.
   PubMed Web of Science ®Google Scholar
• Crews S, Barth R, Hood L, et al. Mouse c-myc oncogene is located on chromosome 15 and translocated to chromosome 12 in plasmacytomas. Science. 1982;218(4579):1319–1321.
   PubMed Web of Science ®Google Scholar
• Brägelmann J, Böhm S, Guthrie MR, et al. Family matters: how MYC family oncogenes impact small cell lung cancer. Cell Cycle. 2017; [Internet]. 16(16),1489–1498. Available from: https://www.tandfonline.com/doi/full/10.1080/15384101.2017.1339849
   PubMed Web of Science ®Google Scholar
• Zimmerman KA, Yancopoulos GD, Collum RG, et al. Differential expression of myc family genes during murine development. Nature. 1986;319(6056):780–783.
   PubMed Web of Science ®Google Scholar
• Loke SL, Neckers LM, Schwab G, et al. c-myc protein in normal tissue. effects of fixation on its apparent subcellular distribution. Am J Pathol. 1988;131(1):29–37.
   PubMed Web of Science ®Google Scholar
• Greil R, Fasching B, Loidl P, et al. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. Blood. 1991;78(1):180–191.
   PubMed Web of Science ®Google Scholar
• Baudino TA, McKay C, Pendeville-Samain H, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002;16(19):2530–2543.
   PubMed Web of Science ®Google Scholar
• Dong J, Sutor S, Jiang G, et al. c-Myc regulates self-renewal in bronchoalveolar stem cells. PLoS ONE. 2011;6(8):e23707.
   PubMed Web of Science ®Google Scholar
• Tseng -Y-Y, Moriarity BS, Gong W, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014 Aug 7;512(7512):82–86. DOI:10.1038/nature13311.
   Google Scholar
• Kohl NE, Kanda N, Schreck RR, et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell. 1983;35(2 Pt 1):359–367.
   PubMed Web of Science ®Google Scholar
• Cohn SL, Salwen H, Quasney MW, et al. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification. Oncogene. 1990;5(12):1821–1827.
   PubMed Web of Science ®Google Scholar
• Schwab M, Varmus HE, Bishop JM, et al. Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. Nature. 1984;308(5956):288–291.
   PubMed Web of Science ®Google Scholar
• Yancopoulos GD, Nisen PD, Tesfaye A, et al. N-myc can cooperate with ras to transform normal cells in culture. Proc Natl Acad Sci USA. 1985;82(16):5455–5459.
   PubMed Web of Science ®Google Scholar
• Malynn BA, de Alboran IM, O’Hagan RC, et al. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 2000;14(11):1390–1399.
   PubMed Web of Science ®Google Scholar
• Westermann F, Muth D, Benner A, et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 2008;9(10):R150.
   PubMed Web of Science ®Google Scholar
• Okubo T. Nmyc plays an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation and differentiation. Development. 2005;132(6):1363–1374.
   PubMed Web of Science ®Google Scholar
• Stanton BR, Perkins AS, Tessarollo L, et al. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev. 1992;6(12A):2235–2247.
   PubMed Web of Science ®Google Scholar
• Nau MM, Brooks BJ, Battey J, et al. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature. 1985;318(6041):69–73.
   PubMed Web of Science ®Google Scholar
• DePinho RA, Hatton KS, Tesfaye A, et al. The human myc gene family: structure and activity of L-myc and an L-myc pseudogene. Genes Dev. 1987;1(10):1311–1326.
   PubMed Web of Science ®Google Scholar
• Ikegaki N, Minna J, Kennett RH. The human L-myc gene is expressed as two forms of protein in small cell lung carcinoma cell lines: detection by monoclonal antibodies specific to two myc homology box sequences [Internet]. Embo J. 1989;8(6),1793–1799. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=2548855&retmode=ref&cmd=prlinks.
   PubMed Web of Science ®Google Scholar
• Prochownik EV, VanAntwerp ME. Differential patterns of DNA binding by myc and max proteins. Proc Natl Acad Sci USA. 1993;90(3):960–964.
   PubMed Web of Science ®Google Scholar
• Hatton KS, Mahon K, Chin L, et al. Expression and activity of L-Myc in normal mouse development. Mol Cell Biol. 1996;16(4):1794–1804.
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Shimizu E, Sumitomo K, et al. L-Myc overexpression and detection of auto-antibodies against L-Myc in both the serum and pleural effusion from a patient with non-small cell lung cancer. Intern Med. 1997;36(10):724–727.
   PubMed Web of Science ®Google Scholar
• Krystal G, Birrer M, Way J, et al. Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer. Mol Cell Biol. 1988;8(8):3373–3381.
   PubMed Web of Science ®Google Scholar
• Kelly K, Cochran BH, Stiles CD, et al. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell. 1983;35(3 Pt 2):603–610.
   PubMed Web of Science ®Google Scholar
• Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol. 1994;14(8):5510–5522.
   PubMed Web of Science ®Google Scholar
• Hasmall SC, Pyrah IT, Soames AR, et al. Expression of the immediate-early genes, c-fos, c-jun, and c-myc: a comparison in rats of nongenotoxic hepatocarcinogens with noncarcinogenic liver mitogens. Fundam Appl Toxicol. 1997;40(1):129–137.
   PubMedGoogle Scholar
• Beltran H. The N-Myc oncogene: maximizing its targets, regulation, and therapeutic potential. Mol Cancer Res. 2014;12(6):815–822.
   PubMed Web of Science ®Google Scholar
• Dingar D, Tu WB, Resetca D, et al. MYC dephosphorylation by the PP1/PNUTS phosphatase complex regulates chromatin binding and protein stability. Nat Comms. 2018;9(1):3502.
   PubMedGoogle Scholar
• De Melo J, Kim SS, Lourenco C, et al. Lysine-52 stabilizes the MYC oncoprotein through an SCFFbxw7-independent mechanism. Oncogene. 2017 Dec 7;36(49):6815–6822.
   PubMed Web of Science ®Google Scholar
• Gargano B, Amente S, Majello B, et al. P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle. 2007;6(16):2031–2037.
   PubMed Web of Science ®Google Scholar
• Yada M, Hatakeyama S, Kamura T, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. Embo J. 2004;23(10):2116–2125.
   PubMed Web of Science ®Google Scholar
• Campbell GR, Zimmerman K, Blank RD, et al. Chromosomal location of N-myc and L-myc genes in the mouse. Oncogene Res. 1989;4(1):47–54.
   PubMedGoogle Scholar
• Zelinski T, Verville G, White L, et al. Confirmation of the assignment of MYCL to chromosome 1 in humans and its position relative to RH, UMPK, and PGM1. Genomics. 1988;2(2):154–156.
   PubMedGoogle Scholar
• Rottmann S, Lüscher B. The Mad side of the Max network: antagonizing the function of Myc and more. Curr Top Microbiol Immunol. 2006;302:63–122.
   PubMed Web of Science ®Google Scholar
• Ayer DE, Eisenman RN. A switch from Myc: Maxto Mad: maxheterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev. 1993;7(11):2110–2119. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=8224841&retmode=ref&cmd=prlinks
   Google Scholar
• Zhu J, Blenis J, Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci. 2008;105(18):6584–6589.
   PubMed Web of Science ®Google Scholar
• Kalkat M, De Melo J, Hickman KA, et al. MYC deregulation in primary human cancers. Genes (Basel). 2017;8:6.
   Web of Science ®Google Scholar
• Murphy DJ, Junttila MR, Pouyet L, et al. Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell. 2008;14(6):447–457. [Internet]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S153561080800367X
   PubMed Web of Science ®Google Scholar
• Richardson GE, Johnson BE. The biology of lung cancer. YSONC. 1993;20(2):105–127.
   Google Scholar
• Broers JL, Viallet J, Jensen SM, et al. Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol. 1993;9(1):33–43.
   PubMed Web of Science ®Google Scholar
• Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107–1120.
   PubMed Web of Science ®Google Scholar
• Network TCGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31;511(7511):543–550.
   Web of Science ®Google Scholar
• Jiang R, Wang X, Jin Z, et al. Association of nuclear PIM1 expression with lymph node metastasis and poor prognosis in patients with lung adenocarcinoma and squamous cell carcinoma. J Cancer. 2016;7(3):324–334.
   PubMed Web of Science ®Google Scholar
• Kiani A, Abedini A, Adcock IM, et al. Association between vitamin D deficiencies in sarcoidosis with disease activity, course of disease and stages of lung involvements. J Med Biochem. 2018;37(2):103–109.
   PubMed Web of Science ®Google Scholar
• Volm M, Koomagi R. Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer. Oncol Rep. 2000;7(1):95–98.
   PubMed Web of Science ®Google Scholar
• Kubokura H, Tenjin T, Akiyama H, et al. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization. Ann Thorac Cardiovasc Surg. 2001;7(4):197–203.
   PubMedGoogle Scholar
• Rapp UR, Korn C, Ceteci F, et al. Myc is a metastasis gene for non-small-cell lung cancer. PLoS ONE. 2009;4(6):e6029–16.
   PubMed Web of Science ®Google Scholar
• Volm M, van Kaick G, Mattern J. Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases. Clin Exp Metastasis. 1994;12(4):329–334.
   PubMed Web of Science ®Google Scholar
• Seo AN, Yang JM, Kim H, et al. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas. Br J Cancer. 2014;110(11):2688–2699.
   PubMed Web of Science ®Google Scholar
• Wolfer A, Wittner BS, Irimia D, et al. MYC regulation of a “poor-prognosis” metastatic cancer cell state. Proc Natl Acad Sci USA. 2010;107(8):3698–3703.
   PubMed Web of Science ®Google Scholar
• Dehan E, Ben-Dor A, Liao W, et al. Chromosomal aberrations and gene expression profiles in non-small cell lung cancer. Lung Cancer. 2007;56(2):175–184.
   PubMed Web of Science ®Google Scholar
• Flacco A, Ludovini V, Bianconi F, et al. MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer. Am J Clin Oncol. 2015;38(2):152–158. [Internet]. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25806711&retmode=ref&cmd=prlinks
   PubMed Web of Science ®Google Scholar
• Yoo JY, Kim CH, Song SH, et al. Expression of caspase-3 and c-myc in non-small cell lung cancer. Cancer Res Treat. 2004;36(5):303–307.
   PubMedGoogle Scholar
• Perez EA, Jenkins RB, Dueck AC, et al. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol. 2011;29(6):651–659.
   PubMed Web of Science ®Google Scholar
• Zitterbart K, Filkova H, Tomasikova L, et al. Low-level copy number changes of MYC genes have a prognostic impact in medulloblastoma. J Neurooncol. 2011;102(1):25–33.
   PubMed Web of Science ®Google Scholar
• Zhang X, Choi PS, Francis JM, et al. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet. 2016;48(2):176–182.
   PubMed Web of Science ®Google Scholar
• Tabor V, Bocci M, Alikhani N, et al. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence. Cancer Res. 2014;74(16):4222–4229.
   PubMed Web of Science ®Google Scholar
• Alidousty C, Baar T, Martelotto LG, et al. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations. J Pathol. 2018;246(1):67–76. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29885057&retmode=ref&cmd=prlinks.
   Google Scholar
• Konishi H, Kozaki K, Osada H, et al. Molecular analysis of a Myc antagonist, ROX/ Mnt,at 17p13.3 in human lung cancers. Jpn J Cancer Res. 1998;89(4):347–351.
   PubMedGoogle Scholar
• Tsai L-H, Wu J-Y, Cheng Y-W, et al. The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss. Oncogene. 2015;34(13):1641–1649.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Carney DN, Nau MM, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 1985;45(6):2924–2930.
   PubMed Web of Science ®Google Scholar
• Johnson BE, Russell E, Simmons AM, et al. MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J Cell Biochem Suppl. 1996;24:210–217.
   PubMedGoogle Scholar
• Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104–1110. Internet. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=22941188&retmode=ref&cmd=prlinks
   PubMed Web of Science ®Google Scholar
• Sos ML, Dietlein F, Peifer M, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences. 2012;109(42):17034–17039.
   PubMed Web of Science ®Google Scholar
• Iwakawa R, Takenaka M, Kohno T, et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes, Chromosomes and Cancer. 2013;52(9):802–816.
   PubMed Web of Science ®Google Scholar
• de Cássia SAR, Meurer RT, Roehe AV. MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study. J Cancer Res Clin Oncol. 2014;140(12):2021–2025.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44(10):1111–1116.
   PubMed Web of Science ®Google Scholar
• Brennan J, O’Connor T, Makuch RW, et al. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res. 1991;51(6):1708–1712.
   PubMed Web of Science ®Google Scholar
• Kim YH, Girard L, Giacomini CP, et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene. 2006;25(1):130–138.
   PubMed Web of Science ®Google Scholar
• Dammert MA, Brägelmann J, Olsen RR, et al. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nat Commun. 2019;10(1):3485. Available from: http://www.nature.com/articles/s41467-019-11371-x.
   Google Scholar
• McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, et al. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell. 2014;156(6):1298–1311.
   PubMed Web of Science ®Google Scholar
• Calbo J, van Montfort E, Proost N, et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell. 2011;19(2):244–256.
   PubMed Web of Science ®Google Scholar
• Schwab M, Varmus HE, Bishop JM. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature. 1985;316(6024):160–162.
   PubMed Web of Science ®Google Scholar
• Barrett J, Birrer MJ, Kato GJ, et al. Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol. 1992;12(7):3130–3137.
   PubMed Web of Science ®Google Scholar
• Kim D-W, Wu N, Kim Y-C, et al. Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer. Genes Dev. 2016;30(11):1289–1299.
   PubMed Web of Science ®Google Scholar
• Murphy DM, Buckley PG, Bryan K, et al. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS ONE. 2009;4(12):e8154.
   PubMed Web of Science ®Google Scholar
• Romero OA, Torres-Diz M, Pros E, et al. MAX inactivation in small-cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov. 2014 Mar;4(3):292–303.
   PubMed Web of Science ®Google Scholar
• Whitfield JR, Beaulieu M-E, Soucek L. Strategies to inhibit Myc and their clinical applicability. Front Cell Dev Biol. 2017;5:10.
   PubMed Web of Science ®Google Scholar
• Drygin D, Siddiqui-Jain A, O’Brien S, et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res. 2009;69(19):7653–7661.
   PubMed Web of Science ®Google Scholar
• Tsai C-Y, Sun S, Zhang H, et al. APTO-253 is a new addition to the repertoire of drugs that can exploit DNA BRCA1/2 deficiency. Mol Cancer Ther. 2018;17(6):1167–1176.
   PubMed Web of Science ®Google Scholar
• Bidwell GL, Perkins E, Hughes J, et al. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS ONE. 2013;8(1):e55104.
   PubMed Web of Science ®Google Scholar
• Soucek L, Whitfield J, Martins CP, et al. Modelling Myc inhibition as a cancer therapy. Nature. 2008;455(7213):679–683.
   PubMed Web of Science ®Google Scholar
• Kato F, Fiorentino FP, Alibés A, et al. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Oncotarget. 2016;7(47):77378–77388.
   PubMedGoogle Scholar
• Hsu W-H, Zhao X, Zhu J, et al. Checkpoint Kinase 1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in SCLC by promoting mitotic cell death. J Thorac Oncol. 2019;14(6):1032–1045.
   PubMed Web of Science ®Google Scholar
• Wang J, Ma S, Chen X, et al. The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling. Invest New Drugs. 2019;37(5):828–836.
   PubMed Web of Science ®Google Scholar
• Bian C, Liu Z, Li D, et al. PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer. Oncol Lett. 2018;15(6):9655–9662.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012;22(3):345–358.
   PubMed Web of Science ®Google Scholar
• Chen B-J, Wu Y-L, Tanaka Y, et al. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci. 2014;10(10):1084–1096.
   PubMed Web of Science ®Google Scholar
• Dutta D, Debnath M, Muller D, et al. Cell penetrating thiazole peptides inhibit c-MYC expression via site-specific targeting of c-MYC G-quadruplex. Nucleic Acids Res. 2018;46(11):5355–5365.
   PubMed Web of Science ®Google Scholar
• Local A, Zhang H, Benbatoul KD, et al. APTO-253 stabilizes G-quadruplex DNA, inhibits MYC expression, and induces DNA damage in acute myeloid leukemia cells. Mol Cancer Ther. 2018;17(6):1177–1186.
   PubMed Web of Science ®Google Scholar
• Ozcan G, Ozpolat B, Coleman RL, et al. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015;87:108–119.
   PubMed Web of Science ®Google Scholar
• Struntz NB, Chen A, Deutzmann A, et al. Stabilization of the Max homodimer with a small molecule attenuates Myc-driven transcription. Cell Chem Biol. 2019;26(5):711–723.e14.
   PubMed Web of Science ®Google Scholar
• Bidwell GL, Perkins E, Hughes J, Khan M, James JR, Raucher D. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model. PLoS One. 2013;8(1):e55104
   PubMed Web of Science ®Google Scholar
• Montagne M, Beaudoin N, Fortin D, et al. The Max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities [Internet]. PLoS ONE. 7(2), e32172 (2012). Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=22384171&retmode=ref&cmd=prlinks.
   PubMed Web of Science ®Google Scholar
• Soucek L, Helmer-Citterich M, Sacco A, et al. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene. 1998;17(19):2463–2472.
   PubMed Web of Science ®Google Scholar
• Beaulieu M-E, Jauset T, Massò-Vallés D, et al. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Sci Transl Med. 2019;11:484.
   Web of Science ®Google Scholar
• Fiorentino FP, Tokgün E, Solé-Sánchez S, et al. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget. 2016;7(21):31014–31028.
   PubMedGoogle Scholar
• Soucek L, Whitfield JR, Sodir NM, et al. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013;27(5):504–513.
   PubMed Web of Science ®Google Scholar
• Adeegbe DO, Liu S, Hattersley MM, et al. BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in kras-mutant non-small cell lung cancer. Cancer Immunol Res. 2018;6(10):1234–1245.
   PubMed Web of Science ®Google Scholar
• Jauset T, Massò-Vallés D, Martínez-Martín S, et al. BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Oncotarget. 2018;9(27):18734–18746.
   PubMedGoogle Scholar
• Lockwood WW, Zejnullahu K, Bradner JE, et al. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proceedings of the National Academy of Sciences. 2012;109(47):19408–19413.
   PubMed Web of Science ®Google Scholar
• Alqahtani A, Choucair K, Ashraf M, et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019;5(3):FSO372.
   PubMed Web of Science ®Google Scholar
• Pervaiz M, Mishra P, Gunther S. Bromodomain drug discovery - the past, the present, and the future. Chem Rec. 2018;18(12):1808–1817.
   PubMed Web of Science ®Google Scholar
• Sen T, Tong P, Stewart CA, et al. CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or Olaparib. Cancer Res. 2017;77(14):3870–3884.
   PubMed Web of Science ®Google Scholar
• Otto T, Horn S, Brockmann M, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell. 2009;15(1):67–78.
   PubMed Web of Science ®Google Scholar
• Chipumuro E, Marco E, Christensen CL, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126–1139.
   PubMed Web of Science ®Google Scholar
• Garcia-Cuellar MP, Fuller E, Mathner E, et al. Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia. Leukemia. 2014;28(7):1427–1435.
   PubMed Web of Science ®Google Scholar
• Christensen CL, Kwiatkowski N, Abraham BJ, et al. Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. Cancer Cell. 2014;26(6):909–922.
   PubMed Web of Science ®Google Scholar
• Chalishazar MD, Wait SJ, Huang F, et al. MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion. Clin Cancer Res. 2019;25(16):5107–5121.
   PubMed Web of Science ®Google Scholar
• Popov N, Wanzel M, Madiredjo M, et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol. 2007;9(7):765–774. Internet. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17558397
   PubMed Web of Science ®Google Scholar
• Sun XX, He X, Yin L, et al. The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc. Proc Natl Acad Sci. 2015;112(12):3734–3739.
   PubMed Web of Science ®Google Scholar
• Tavana O, Li D, Dai C, et al. HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma. Nat Med. 2016;22(10):1180–1186.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xu B, Qiang Y, et al. Overexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growth. J Cell Mol Med. 2015;19(4):799–805.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Gandara DR, Antonia SJ, et al. Non-small-cell lung cancer: role of the immune system and potential for immunotherapy. J Thorac Oncol. 2015;10(7):974–984.
   PubMed Web of Science ®Google Scholar
• Casacuberta-Serra S, Soucek L. Myc and Ras, the Bonnie and Clyde of immune evasion. Transl Cancer Res. 2018;7(Suppl 4):S457–S459.
   PubMedGoogle Scholar
• Casey SC, Baylot V, Felsher DW. The MYC oncogene is a global regulator of the immune response. Blood. 2018;131(18):2007–2015.
   PubMed Web of Science ®Google Scholar
• Rakhra K, Bachireddy P, Zabuawala T, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell. 2010;18(5):485–498.
   PubMed Web of Science ®Google Scholar
• Casey SC, Tong L, Li Y, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016;352(6282):227–231.
   PubMed Web of Science ®Google Scholar
• Kim EY, Kim A, Kim SK, et al. MYC expression correlates with PD-L1 expression in non-small cell lung cancer. Lung Cancer. 2017;110:63–67.
   PubMed Web of Science ®Google Scholar
• Kortlever RM, Sodir NM, Wilson CH, et al. Myc cooperates with ras by programming inflammation and immune suppression. Cell. 2017;171(6):1301–1315.e14.
   PubMed Web of Science ®Google Scholar
• Topper MJ, Vaz M, Chiappinelli KB, et al. Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung cancer. Cell. 2017;171(6):1284–1300.e21.
   PubMed Web of Science ®Google Scholar
• Anagnostou V, Smith KN, Forde PM, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017;7(3):264–276.
   PubMed Web of Science ®Google Scholar